The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRM.sup.N0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRM.sup.N0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides (“branched-RBP”).

The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages that target oncogenic (tumorigenic) bacteria, and use of the same for treating or preventing cancer.

Disclosed herein are compositions comprising bacteriophages and methods of using these compositions for treating NTM infections. The present disclosure also provides compositions for screening bacteriophages that are effective in treating NTM infections and methods of using the same.

The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcus garvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcus garvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.

An antibacterial formulation having a mixture of bacteriophages with lytic activity against strains of Salmonella spp. and a pharmaceutically and veterinarily acceptable vehicle, pH stabilizer and/or excipients. This formulation is for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars; use and method for preventing or treating infectious diseases caused by Salmonella spp. in farm animals by administering the antibacterial formulation to a non-human animal orally.

Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.

A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×10.sup.9 PFU/ml) for use in therapeutic applications.